Abstract
At present, faecal microbiota transplantation is not approved by the US Food and Drug Administration for any indication in the USA, but can be used to prevent recurrent Clostridioides difficile infection according to the policy of enforcement discretion. Use of faecal microbiota transplantation is currently reserved for patients with multiple recurrent C difficile, defined as three or more episodes in total. Considering the success of this treatment, high efficacy, and reasonable safety profile of faecal microbiota transplantation, should this therapy be offered at an earlier stage in the treatment framework? Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trialIn patients with first or second C difficile infection, first-line faecal microbiota transplantation is highly effective and superior to the standard of care vancomycin alone in achieving sustained resolution from C difficile. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
